Key result
Coronary artery stenting for variant angina refractory to triple drug therapy yielded favorable clinical and angiographic results without intrastent restenosis at 4 months.
Why the study?
Does coronary artery stenting improve clinical and angiographic outcomes in patients with variant angina refractory to medical therapy?
Case Report
Does coronary artery stenting improve clinical and angiographic outcomes in patients with variant angina refractory to medical therapy?
Coronary stenting may be a viable unconventional treatment option for variant angina refractory to triple medical therapy, though long-term data is required.
May offer option in refractory variant angina; leaves open need for controlled trials before practice change.
Pharmacological therapy remains the treatment of choice for Prinzmetal angina. We report an unconventional approach of coronary artery stenting to treat coronary artery spasm in variant angina refractory to triple drug therapy. Favorable clinical and angiographic results and a negative Ergonovine test, under less aggressive medical therapy, are valuable arguments for stenting. Four-month angiographic follow-up showed absence of intrastent restenosis with a negative Ergonovine test. However, long-term follow-up is necessary before advocating this as a systematic approach.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (1998) conducted a case report in Variant angina refractory to triple drug therapy. Coronary artery stenting was evaluated on Clinical and angiographic results, Ergonovine test, and intrastent restenosis. Coronary artery stenting for variant angina refractory to triple drug therapy yielded favorable clinical and angiographic results without intrastent restenosis at 4 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: